FDA allows wider use of 2 hepatitis drugs from Schering

03/11/2009 | Forbes

Schering-Plough received FDA clearance to market its hepatitis C drugs Pegintron and Rebetol for patients with compensated liver disease who no longer respond to previous treatment. The drugs are approved as initial treatment in patients age 3 and older.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC